CD8A and adenocarcinoma: Similarly, patients progressed to adenocarcinoma displayed increased CD20+ (p < 0.001), CD4+ (p = 0.003) and CD8+ (p = 0.014) lymphocytes in the background non-dysplastic BO compared with non-progressors.